Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Terms of Reference of the Nomination Committee under the Board of Directors

Terms of Reference of the Audit Committee under the Board of Directors

Overseas Regulatory Announcement-Announcement on Phloroglucinol Injection Having Obtained Drug Registration Certificate

OversOverseas Regulatory Announcement-Announcement on Valsartan Capsules Having Obtained the Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Oseltamivir Phosphate for Suspension having obtained Drug Registration Certificate

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025

Overseas Regulatory Announcement-Announcement on Prednisolone Acetate having obtained the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients

Overseas Regulatory Announcement-Announcement on Epinephrine Hydrochloride Injection Having Passed Generics Consistency Evaluation

Overseas Regulatory Announcement-Announcement on Lidocaine and Prilocaine Cream having obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Vonoprazan Fumarate having obtained the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients

总条数: 87条

＜ 1 ... 4 5 6 ... 9 ＞

跳转到: 页